Cwm LLC Acquires 637 Shares of Haemonetics Corporation $HAE

Cwm LLC grew its holdings in Haemonetics Corporation (NYSE:HAE) by 53.5% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,827 shares of the medical instruments supplier’s stock after acquiring an additional 637 shares during the quarter. Cwm LLC’s holdings in Haemonetics were worth $136,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Quarry LP raised its stake in Haemonetics by 63.4% in the 1st quarter. Quarry LP now owns 495 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 192 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Haemonetics by 59.4% in the second quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier’s stock valued at $33,000 after buying an additional 165 shares in the last quarter. UMB Bank n.a. raised its position in shares of Haemonetics by 91.7% in the second quarter. UMB Bank n.a. now owns 669 shares of the medical instruments supplier’s stock valued at $50,000 after buying an additional 320 shares in the last quarter. University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Haemonetics in the first quarter valued at approximately $65,000. Finally, Strs Ohio acquired a new stake in shares of Haemonetics in the first quarter valued at approximately $140,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Stock Up 1.1%

Shares of NYSE HAE opened at $49.99 on Friday. The stock has a 50-day moving average price of $51.40 and a two-hundred day moving average price of $62.15. The company has a market cap of $2.41 billion, a price-to-earnings ratio of 15.29, a PEG ratio of 0.91 and a beta of 0.37. Haemonetics Corporation has a 12 month low of $47.31 and a 12 month high of $94.99. The company has a current ratio of 1.72, a quick ratio of 1.04 and a debt-to-equity ratio of 1.04.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.09. The business had revenue of $321.39 million during the quarter, compared to analysts’ expectations of $305.12 million. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The firm’s quarterly revenue was down 4.4% compared to the same quarter last year. During the same period in the prior year, the company earned $1.02 EPS. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. As a group, analysts forecast that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Raymond James Financial cut Haemonetics from a “strong-buy” rating to an “outperform” rating and dropped their price objective for the company from $105.00 to $78.00 in a report on Monday, August 11th. Barrington Research reaffirmed an “outperform” rating and issued a $86.00 price target on shares of Haemonetics in a research note on Tuesday, October 21st. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $62.00 price target (down previously from $85.00) on shares of Haemonetics in a research note on Friday, August 8th. Weiss Ratings cut shares of Haemonetics from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Saturday, October 25th. Finally, Citigroup dropped their target price on shares of Haemonetics from $78.00 to $64.00 and set a “buy” rating for the company in a research report on Tuesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Haemonetics has a consensus rating of “Moderate Buy” and a consensus price target of $75.89.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.